Möchten Sie immer auf dem neuesten Stand bleiben?
Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.
-
UK Market Entry: MHRA registration authorizes hp+detect™ for commercial sale in Great BritainActive Commercialization: Biomerica is in active discussions with UK partners to access the diagnostic...
-
Key Highlights Responder Analysis: 59.4% of patients achieved ≥30% reduction in abdominal pain; 68.1% achieved ≥30% reduction in bloating—using the FDA-recognized responder endpoint consistent...
-
Approval Marks Biomerica’s Strategic Entry into Southeast Asia’s Rapidly Growing Healthcare MarketSimple, FDA-Cleared At-Home Test Detects an Early Warning Sign of Colorectal Cancer in Minutes ...
-
FY26 Q2 Earnings Release
-
CMS is the single largest payer for healthcare in the United States, with Medicare responsible for approximately 21% of total healthcare expenditure.The $300 rate will apply to claims approved and...
-
Authorization Covers Multiple Screening Tests for Cancer and Chronic Disease Risk Detection • Portfolio includes tests for colorectal disease, breast self exam, prostate disease, kidney disease, and...
-
Publication details large multicenter clinical trial demonstrating significant reductions in IBS symptoms through inFoods IBS guided dietary therapy IRVINE, Calif., Nov. 25, 2025 (GLOBE NEWSWIRE)...
-
Rising Demand from Third-Party Diagnostic and Biotechnology Companies Drives CDMO Service ExpansionComprehensive CDMO services now featured on Biomerica’s updated website IRVINE, Calif., Nov. 06,...
-
- Expands Marketing of Non-Drug IBS Symptom Management Test Through One of the Nation’s Most Trusted Health Care Distributors- Relationship Marks a Key Milestone in Biomerica’s Commercialization...
-
Biomerica reports Q1 FY2026 results highlighting improved margins, cost reductions, and progress in advancing diagnostics and CDMO operations.